Orphalan

Executive Summary

Orphalan is a French pharmaceutical company founded in 2011, dedicated to developing and commercializing innovative therapies for rare diseases. Its lead product, Cuprior®/Cuvrior® (trientine tetrahydrochloride), is approved for the treatment of Wilson disease, a rare genetic disorder of copper metabolism. The company has established a global footprint, with headquarters in Paris and operations aimed at improving patient access to orphan medications. As a private company, Orphalan focuses on addressing unmet medical needs in niche therapeutic areas. With a commercial-stage product and a targeted strategy, Orphalan is positioned to grow its presence in the rare disease market, though its pipeline beyond Wilson disease remains undisclosed. The company's success hinges on expanding market penetration, securing reimbursement in key territories, and potentially advancing additional rare disease candidates.

Upcoming Catalysts (preview)

• 2026Regulatory approval or expanded access for Cuprior in additional countries70% success
• 2027Pediatric or new formulation extension for Wilson disease40% success
• TBDInitiation or update on pipeline programs for other rare diseases50% success